Vertex Pharmaceuticals Payments to acquire available-for-sale debt securities remained flat by 0.0% to $1.60B in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 14.0%, from $1.86B to $1.60B. Over 2 years (FY 2023 to FY 2025), Payments to acquire available-for-sale debt securities shows an upward trend with a 30.0% CAGR.
An increase indicates the company is actively managing its cash reserves by investing in liquid assets, while a decrease may suggest a shift toward other uses of capital.
This metric tracks the cash outflow used to purchase available-for-sale debt securities as part of the company's treasur...
Standard treasury management metric; common for cash-rich biotech firms managing large balance sheets.
is_jpm_payments_to_acquire_afs_securities| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $3.79B | $7.44B | $6.40B |
| YoY Change | — | +96.4% | -14.0% |
We use cookies for analytics. See our Privacy and Cookie Policy.